<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="509">
  <stage>Registered</stage>
  <submitdate>11/09/2005</submitdate>
  <approvaldate>21/09/2005</approvaldate>
  <actrnumber>ACTRN12605000454673</actrnumber>
  <trial_identification>
    <studytitle>Does the use of nizatidine (Tazac) as a prokinetic agent improve gastric emptying in patients who have had an oesophagectomy for oesophageal cancer?</studytitle>
    <scientifictitle>Does the use of nizatidine (Tazac) as a prokinetic agent improve gastric emptying in patients who have had an oesophagectomy for oesophageal cancer?</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Study Number 07-09-08-04</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Delayed gastric emptying post oesophagectomy for oesophageal cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Oesophageal (gullet)</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions />
    <comparator />
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To see if there is a statistically significant improvement in gastric emptying by 20% with the use of nizatidine, compared with baseline function after one week of use.</outcome>
      <timepoint />
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>To assess patients' quality of life and eating comfort</outcome>
      <timepoint>Prior to the start of the study, and after one week on nizatidine.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria> 6 months or more post oesophagectomy- written consent.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Allergy to nizatidine- patients undergoing further treatment for oesophageal cancer- patients who are mentally or legally incapacitated- all pregnant women or potentially pregnant women.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>1/12/2004</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>20</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Cabrini Clinical Education and Research Institute</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Other</fundingtype>
      <fundingname>Cabrini Clinical Education and Research Institute Council</fundingname>
      <fundingaddress />
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>University</sponsortype>
      <sponsorname>Cabrini Monash University Department of Surgery</sponsorname>
      <sponsoraddress />
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this project is to see whether nizatidine, a drug commonly used to treat peptic ulcers and reflux disease, may improve the emptying of the stomach in patients who have had an operation for oesophageal cancer. Participation in this project involves taking the trial medication for one week and having a special gastric empyting scan before and after one week of treatment with the drug. The scan involves a small dose of radiation which has been approved by the Department of Human Services, Radiation Safety Approval.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Cabrini Human Research Ethics Committee Department of Human Services - Radiation Safety Program</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Mr Simon Woods</name>
      <address>Cabrini Hospital
Suite 20
183 Wattletree Road
Malvern VIC 3144</address>
      <phone>+61 3 95761411</phone>
      <fax>+61 3 95761414</fax>
      <email>woods@surgicalconsulting.com.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Jennifer Chong</name>
      <address>Cabrini Hospital
Suite 20
183 Wattletree Road
Malvern VIC 3144</address>
      <phone>+61 3 95081651</phone>
      <fax>+61 3 95081657</fax>
      <email>jwcho7@hotmail.com</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>